Vol 5, No 2 (2020)
Review article
Published online: 2020-05-22
Material engineering for atopic dermatitis treatment
1
, 1, 1, 1, 1
, 1, 1, 1, 1
Medical Research Journal 2020;5(2):110-115.
Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin disease with a prevalence of 30% for children and to 17% for adults. There is observed an increasing trend of occurring AD over time in the world. Many factors contribute to the development of the disease, such as environmental, genetic and psychological factors. The proper AD treatment should be complexed and consists of skin care with emollients and pharmacological treatment. Most of the topical corticosteroids and other drugs have unpleasant side effects, therefore, developing new therapies is very useful. To minimalize side effects with a simultaneous reduction in the duration, a NPs (nanoparticles) therapy application is highly proposed. On the other hand, hydrogels and their shielding properties with high hydrating level and drug delivery capability are also widely studied. Some works report on the combination of these two solutions with promising results. Material engineering for biomedical applications is a dynamically growing field which offers new drug delivery systems (DDS). In this paper, based on the literature we discuss the new methods of AD treatment using hydrogels and nanotechnology.
Keywords: atopic dermatitisdrug delivery systemnanoparticleshydrogels
References
- Wang C, Kraus CN, Patel KG, et al. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records. Int J Dermatol. 2020; 59(2): 253–256.
- Yeom M, Ahn S, Oh JY, et al. Atopic dermatitis induces anxiety- and depressive-like behaviors with concomitant neuronal adaptations in brain reward circuits in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2020; 98: 109818.
- Jaworek AK, Jaworek M, Makara-Studzińska M, et al. Depression and Serum Content of Serotonin in Adult Patients with Atopic Dermatitis. Adv Exp Med Biol. 2020 [Epub ahead of print].
- Pezzolo E, Naldi L. Epidemiology of major chronic inflammatory immune-related skin diseases in 2019. Expert Rev Clin Immunol. 2020; 16(2): 155–166.
- González-Tarancón R, Sanmartín R, Lorente F, et al. Prevalence of FLG loss-of-function mutations R501X, 2282del4, and R2447X in Spanish children with atopic dermatitis. Pediatr Dermatol. 2020; 37(1): 98–102.
- Margolis DJ, Mitra N, Wubbenhorst B, et al. Filaggrin sequencing and bioinformatics tools. Arch Dermatol Res. 2020; 312(2): 155–158.
- Rodrigues MA, Torres T. JAK/STAT inhibitors for the treatment of atopic dermatitis. J Dermatolog Treat. 2020; 31(1): 33–40.
- Stefanovic N, Flohr C, Irvine AD. The exposome in atopic dermatitis. Allergy. 2020; 75(1): 63–74.
- Fuertes E, Flohr C, Silverberg JI, et al. ISAAC Phase Three Study Group. Global Associations between UVR Exposure and Current Eczema Prevalence in Children from ISAAC Phase Three. J Invest Dermatol. 2017; 137(6): 1248–1256.
- Williamson S, Merritt J, De Benedetto A. Atopic dermatitis in the elderly: a review of clinical and pathophysiological hallmarks. Br J Dermatol. 2020; 182(1): 47–54.
- Flohr C, Mann J. New insights into the epidemiology of childhood atopic dermatitis. Allergy. 2014; 69(1): 3–16.
- Grine L, Tochtermann G, Lapeere H, et al. Comparison of Personality Traits among Patients with Psoriasis, Atopic Dermatitis, and Stress: A Pilot Study. Dermatology. 2020 [Epub ahead of print]: 1–5.
- Duran S, Atar E. Determination of depression, anxiety and stress (DAS) levels in patients with atopic dermatitis: a case-control study. Psychol Health Med. 2019 [Epub ahead of print]: 1–11.
- Glatz M, Jo JH, Kennedy EA, et al. Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. PLoS One. 2018; 13(2): e0192443.
- Rademaker M, Agnew K, Andrews M, et al. Managing atopic dermatitis with systemic therapies in adults and adolescents: An Australian/New Zealand narrative. Australas J Dermatol. 2020; 61(1): 9–22.
- Thyssen JP, Berents T, Bradley M, et al. Clinical Management of Atopic Dermatitis in Adults: Mapping of Expert Opinion in 4 Nordic Countries using a Modified Delphi Process. Acta Derm Venereol. 2020; 100(1): adv00015.
- Phan K, Charlton O, Baker C, et al. Dermatologist attitudes toward ciclosporin use in atopic dermatitis. J Dermatolog Treat. 2020 [Epub ahead of print]: 1–3.
- Lopes A, Sokolova A, Abreu C, et al. Atopic Dermatitis Host and Environment Model: Revisiting Therapeutic Options. Eur Ann Allergy Clin Immunol. 2020; 52(1): 4–14.
- Tanei R. Atopic Dermatitis in Older Adults: A Review of Treatment Options. Drugs Aging. 2020; 37(3): 149–160.
- Juarez MC, Grossberg AL. Phototherapy in the Pediatric Population. Dermatol Clin. 2020; 38(1): 91–108.
- Woo TE, Sibley CD. The emerging utility of the cutaneous microbiome in the treatment of acne and atopic dermatitis. J Am Acad Dermatol. 2020; 82(1): 222–228.
- Alexander H, Paller AS, Traidl-Hoffmann C, et al. The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group. Br J Dermatol. 2019 [Epub ahead of print].
- Blicharz L, Usarek P, Młynarczyk G, et al. Is Itch Intensity in Atopic Dermatitis Associated with Skin Colonization by ? Indian J Dermatol. 2020; 65(1): 17–21.
- Souto EB, Dias-Ferreira J, Oliveira J, et al. Trends in Atopic Dermatitis-From Standard Pharmacotherapy to Novel Drug Delivery Systems. Int J Mol Sci. 2019; 20(22).
- Regis E. Nanotechnologia, narodziny nowej nauki, czyli świat cząsteczka po cząsteczce. Prószyński i S-ka, Warszawa 2001.
- Khan I, Saeed K, Khan I. Nanoparticles: Properties, applications and toxicities. Arab J Chem. 2019; 12(7): 908–931.
- Tiwari J, Tiwari R, Kim K. Zero-dimensional, one-dimensional, two-dimensional and three-dimensional nanostructured materials for advanced electrochemical energy devices. Prog Mater Sci. 2012; 57(4): 724–803.
- Tiwari A, Saraf S, Jain A, et al. Basics to advances in nanotherapy of colorectal cancer. Drug Deliv Transl Res. 2020; 10(2): 319–338.
- Mashaghi S, Jadidi T, Koenderink G, et al. Lipid nanotechnology. Int J Mol Sci. 2013; 14(2): 4242–4282.
- Singh D, Singh S, Sahu J, et al. Ceramic nanoparticles: Recompense, cellular uptake and toxicity concerns. Artif Cells Nanomed Biotechnol. 2016; 44(1): 401–409.
- Gharpure S, Akash A, Ankamwar B. A Review on Antimicrobial Properties of Metal Nanoparticles. J Nanosci Nanotechnol. 2020; 20(6): 3303–3339.
- Falagan-Lotsch P, Grzincic EM, Murphy CJ. New Advances in Nanotechnology-Based Diagnosis and Therapeutics for Breast Cancer: An Assessment of Active-Targeting Inorganic Nanoplatforms. Bioconjug Chem. 2017; 28(1): 135–152.
- Siddique MI, Katas H, Jamil A, et al. Potential treatment of atopic dermatitis: tolerability and safety of cream containing nanoparticles loaded with hydrocortisone and hydroxytyrosol in human subjects. Drug Deliv Transl Res. 2019; 9(2): 469–481.
- Zhuo F, Abourehab MAS, Hussain Z. Hyaluronic acid decorated tacrolimus-loaded nanoparticles: Efficient approach to maximize dermal targeting and anti-dermatitis efficacy. Carbohydr Polym. 2018; 197: 478–489.
- Pandey M, Choudhury H, Gunasegaran TAP, et al. Hyaluronic acid-modified betamethasone encapsulated polymeric nanoparticles: fabrication, characterisation, in vitro release kinetics, and dermal targeting. Drug Deliv Transl Res. 2019; 9(2): 520–533.
- Huang PH, Tseng CH, Lin CY, et al. Preparation, characterizations and anti-pollutant activity of 7,3',4'-trihydroxyisoflavone nanoparticles in particulate matter-induced HaCaT keratinocytes. Int J Nanomedicine. 2018; 13: 3279–3293.
- Kang JH, Chon J, Kim YI, et al. Preparation and evaluation of tacrolimus-loaded thermosensitive solid lipid nanoparticles for improved dermal distribution. Int J Nanomedicine. 2019; 14: 5381–5396.
- Wagner I, Geh KJ, Hubert M, et al. Preliminary evaluation of cytosine-phosphate-guanine oligodeoxynucleotides bound to gelatine nanoparticles as immunotherapy for canine atopic dermatitis. Vet Rec. 2017; 181(5): 118.
- Kang H, Kim S, Lee KH, et al. 5 nm Silver Nanoparticles Amplify Clinical Features of Atopic Dermatitis in Mice by Activating Mast Cells. Small. 2017; 13(9).
- Goindi S, Kumar G, Kaur A. Novel flexible vesicles based topical formulation of levocetirizine: in vivo evaluation using oxazolone-induced atopic dermatitis in murine model. J Liposome Res. 2014; 24(3): 249–257.
- Harrison IP, Spada F. Hydrogels for Atopic Dermatitis and Wound Management: A Superior Drug Delivery Vehicle. Pharmaceutics. 2018; 10(2).
- WICHTERLE O, LÍM D. Hydrophilic Gels for Biological Use. Nature. 1960; 185(4706): 117–118.
- Szekalska M, Sosnowska K, Tomczykowa M, et al. In vivo anti-inflammatory and anti-allergic activities of cynaroside evaluated by using hydrogel formulations. Biomed Pharmacother. 2020; 121: 109681.
- Jeong JiH, Back SK, An JH, et al. Topical film prepared with Rhus verniciflua extract-loaded pullulan hydrogel for atopic dermatitis treatment. J Biomed Mater Res B Appl Biomater. 2019; 107(7): 2325–2334.
- Kircik L. The effect of desonide hydrogel on pruritis associated with atopic dermatitis. J Drugs Dermatol. 2014; 13(6): 725–728.
- Wang W, Wat E, Hui PCL, et al. Dual-functional transdermal drug delivery system with controllable drug loading based on thermosensitive poloxamer hydrogel for atopic dermatitis treatment. Sci Rep. 2016; 6: 24112.
- Augustin M, Goepel L, Jacobi A, et al. Efficacy and tolerability of liposomal polyvinylpyrrolidone-iodine hydrogel for the localized treatment of chronic infective, inflammatory, dermatoses: an uncontrolled pilot study. Clin Cosmet Investig Dermatol. 2017; 10: 373–384.
- Napimoga MH, Clemente-Napimoga JT, Machabanski NM, et al. The 15d‑PGJ2 hydrogel ameliorates atopic dermatitis through suppression of the immune response. Mol Med Rep. 2019; 19(6): 4536–4544.